Jazz 2025 JPM Presentation_FINAL.pdf

1、January 2025Innovating to Transform the Lives of Patients and Their Families43rd Annual J.P.Morgan Healthcare ConferenceJanuary 2025MarkellaEPIDIOLEX patient diagnosed with Dravet syndromeJanuary 2025Transforming Lives.Redefining Possibilities.2Caution Concerning Forward-Looking StatementsThis prese

2、ntation contains forward-looking statements and financial targets,including,but not limited to,statements related to:the Companys growth prospects and future financial and operating results,including the ability of the Companys portfolio to drive long-term shareholder value;expectations with respect

3、 to indication expansion opportunities;2024 total,neuroscience and oncology revenue guidance and the Companys expectations related thereto;the Companys ability to drive significant cash flow generation;the Companys commercial expectations,including with respect to revenue diversification and its exp

4、ectations for significant growth;the Companys expectations with respect to the commercial potential of its products and product candidates,including the blockbuster potential for Epidiolex,the peak potential of zanidatamab,growth opportunities for Rylaze,Epidiolex/Epidyolex,Xywav and Ziihera and Zep

5、zelcas potential approval as a first line therapy,and the potential regulatory paths related thereto;the value and growth potential of its products;the Companys net product sales and goals for net product sales from new and acquired products;the Companys views and expectations relating to its patent

6、 portfolio,including with respect to expected patent protection;planned or anticipated clinical trial events,including with respect to initiations,enrollment and data read-outs,and the anticipated timing thereof,and planned or anticipated regulatory submissions and filings and other regulatory matte